CNBC Investing Club: Cramer’s Morning Take on Johnson & Johnson 4/9/26

SPEAKER_1 (0:00)

This episode is brought to you by Schwab Market Update, an original podcast from Charles Schwab. Join host Keith Lansford for this information packed daily market preview delivered in 10 minutes or less, including projected stock updates, monetary policy decisions, and key results and statistics that may impact your trading. Download the latest episode and subscribe at schwab.com/marketupdatepodcast, or find Schwab Market Update wherever you get your podcasts.

SPEAKER_2 (0:29)

What made you confident that you could do something that hadn't been done before? I have no fear of failure.

Julia Boorstin (0:35)

Trailblazing women changing the game.

SPEAKER_4 (0:37)

One of my favorite pieces of advice, think about what your boss's boss needs. Leadership can look in many, many different forms.

Julia Boorstin (0:45)

It really does come down to just trusting yourself. Life is short, and you just gotta think big to accomplish big things. Jeff, Julia Boorstin hosts CNBC Changemakers and Powerplayers. New episodes every Tuesday wherever you get your podcasts.

Jim Cramer (1:01)

Jim Cramer here to share a short preview of my take on the market from today's members-only CNBC Investing Club morning meeting. Join the club for full access to the morning meeting every day at 10:20 a.m. Visit cnbc.com/morningtake to sign up today. That's one word, morning take.

SPEAKER_6 (1:22)

We did raise some cash yesterday through a few different ways, whether it was a trim of Eaton, which is up again today. But we made a pharma swap, sold out of Bristol Myers and bought J&J.

Jim Cramer (1:36)

Bristol had been doing better than J&J?

SPEAKER_6 (1:39)

Over the last six months, yeah, a few steps back. But really the difference here I would say is, look, Bristol, it's a big year. For them, in terms of the pipeline, whether it's several cobenphi readouts, some other key drugs too, they got a hit on these, where J&J, commercial excellence, they have a great portfolio. Now, a great pipeline as well, whether it's the cancer franchise, multiple myeloma.

Jim Cramer (2:07)

The cancer franchise, it's second to none.

SPEAKER_6 (2:09)

Yeah. Neuroscience as well, with actually a competitor to cobenphi. Immunology, a recent oral medication that was recently approved.

Jim Cramer (2:18)

How about the spinoff of a lower multiple business, making so their business would automatically be higher. They did it with Kenview and it jacked up. This was the Kenview, you had the move plus the beating of the plaintiff's bar.

SPEAKER_6 (2:31)

Yeah. So a lot of good things happening at J&J. So I would call it an upgrading of our pharma positions in the portfolio.

Jim Cramer (2:38)

But it is interesting. You can go two ways here. This is apropos of what's happening just this very morning. You can say, okay, listen, I'm going to come into momentum. I'm going to hit the sand disc. I'm going to go with coherent because you want to go with rocket ships. And I love a good rocket ship. And if I were an options trader, I would definitely go for it.

SPEAKER_6 (2:57)

We have a couple of those rocket ships.

Jim Cramer (2:59)

Yes, we do. We have quieter ones. But someone might say, well, Jim, why can't you just go buy momentum? It's obviously going higher. And my problem with that, by the way, is you had momentum just got crushed the other day.

So did Sandus. So you've got to, these are trading vehicles. And I don't like to be in trading vehicles for what we do here as a Charitable Trust.

Julia Boorstin (3:24)

All opinions expressed by Jim Cramer on this podcast and in connection with the CNBC Investing Club are solely Cramer's opinions and do not reflect the opinions of CNBC or its parent company or affiliates and may have been previously disseminated by Cramer on television, radio, internet or another medium. No specific outcome or profit is guaranteed in connection with your reliance upon or other use of the content from Cramer. The opinions offered in connection with this podcast and the CNBC Investing Club are not an attempt to induce any particular trading behavior, investment or strategy. To view the full CNBC Investing Club disclaimer, please visit cnbc.com/investingclubdisclaimer.

SPEAKER_1 (3:56)

Trading at Schwab is powered by Ameritrade, giving you even more specialized support than ever before. Like access to the trade desk, our team of passionate traders ready to tackle anything from the most complex trading questions to a simple strategy gut check. Need assistance? No problem. Get 24-7 professional answers and live help, and access support by phone, email, and in-platform chat. That's how Schwab is here for you to help you trade brilliantly. Learn more at schwab.com/trading.